UNSPSC 51112528: Spiromustine

This classification denotes a nitrogen mustard compound with the molecular formula C14H23Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3HB83X76Z, chemically known as 1,3-diazaspiro(4.5)decane-2,4-dione, 3-(2-(bis(2-chloroethyl)amino)ethyl)- but more generally known as spiromustine, which bears US NIH Compound Identifier 41945. European Medicines Agency schedules Spiromustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10630MIG.

UNSPSC 51112528 Spiromustine, a Commodity code, covers the procurement of this specific chemotherapy agent by state and local health authorities, typically through pharmacy benefit programs, Medicaid agencies, and state employee health plans that manage oncology drug inventories and formularies. State and local governments purchase spiromustine as a line item within broader pharmaceutical procurement frameworks, either directly or through pharmacy benefit managers and group purchasing organizations that aggregate demand across multiple jurisdictions and health plans. The issuing bodies for this code span state health and human services departments, Medicaid agencies, and state employee benefit programs that maintain formulary control and negotiate pricing for cancer therapeutics.

Recent activity centers on Texas, where the Texas Health and Human Services Commission posted RFI HHS0017013 (Request for Information) on April 3, 2026, exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The RFI seeks vendor capabilities for direct contracting with self-insured state employee and retiree health plans, negotiated net pricing models, and outcomes-based contracting approaches for pharmaceutical fulfillment. The solicitation remains preliminary and exploratory; no formal RFP, award value, or binding timeline has been announced, and the state intends to use vendor responses to develop future procurement specifications and implementation strategy for spiromustine and related oncology therapeutics.